Retina

The YOSEMITE/RHINE studies measured changes in the BCVA and CST from baseline to years 1 and 2

The prize, presented by EURETINA and supported by Oculis, will recognise outstanding contributions to retina research

The diagnostic and monitoring tools use artificial intelligence-based models

XLRP often leads to blindness by middle age with no treatment options currently available

The mapping method revealed prominent microscopic abnormalities consistent with DR

Paying attention to high-resolution OCT is more important than ever

The NP-1/NP-1C preloaded IOL injector has already been made available in parts of Asia

Investigators put forth a list of considerations for surgeons ahead of lens removalin paediatric patients

Investigators reported findings from the first study of successful macular hole closure using topical therapy

The flagship, light-based technology has received approval for applications in the anterior and posterior segments

The approval also grants Outlook Therapeutics an initial 10 years of market exclusivity in the EU for bevacizumab gamma (LYTENAVA)

Analysis of the OAKS and DERBY trials showed reduced growth rates of SD-OCT biomarkers for geographic atrophy

Professor Lois accepted the award at the Royal College of Ophthalmologists Annual Congress

The agency issued approval for Yesafili, from Biocon Biologics, and Opuviz, from Samsung Bioepis and Biogen

For decoding biomarkers, a multistage system is just the beginning

Need for accuracy results in optimisation of training for novice surgeons

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March

Allen Ho, MD, presented on the 12-month results of an mutation agnostic optogenetic programme at the ARVO 2024 meeting

Three leaders in glaucoma research, retina care and refractive surgery share their expertise

Incoming ARVO president SriniVas R. Sadda, MD, discussed major challenges in vision science research and how annual meetings inspire innovation in ophthalmology

The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease

Paul Kayne, PhD gave an onsite overview of his poster at the 2024 ARVO meeting

At the ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Giulia Corradetti, MD about AMD

Paolo Silva, MD, speaks on the effect of diabetic retinopathy lesion location and long-term risk of progression

Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation